Keros Therapeutics Posts $1.21/Share Loss in Q1
KROS is trading near its 52-week low of $10.415 (12% above the low).
Summary
Keros Therapeutics announced a first-quarter loss of $1.21 per share. This financial update follows the company's reported net income of $87.0 million for the full year 2025, which was significantly boosted by a Takeda payment. While quarterly losses are typical for a clinical-stage biotechnology firm, this specific Q1 result provides new insight into the company's current operational burn rate. Traders will be evaluating this loss in the context of the company's cash position and ongoing pipeline development, especially after the positive annual performance.
At the time of this announcement, KROS was trading at $11.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $237.3M. The 52-week trading range was $10.42 to $22.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.